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ABSTRACT
A critical problem in leukemia as well as other cancer therapies is the development 
of chemotherapeutic drug-resistance. We have developed models of hematopoietic drug 
resistance that are based on expression of dominant-negative TP53 [TP53 (DN)] or 
constitutively-active MEK1 [MEK1(CA)] oncogenes in the presence of chemotherapeutic 
drugs. In human cancer, functional TP53 activity is often lost in human cancers. 
Also, activation of the Raf/MEK/ERK pathway frequently occurs due to mutations/
amplification of upstream components of this and other interacting pathways. FL5.12 is 
an interleukin-3 (IL−3) dependent hematopoietic cell line that is sensitive to doxorubicin 
(a.k.a Adriamycin). FL/Doxo is a derivative cell line that was isolated by culturing the 
parental FL5.12 cells in doxorubicin for prolonged periods of time. FL/Doxo + TP53 
(DN) and FL/Doxo + MEK1 (CA) are FL/Doxo derivate cell lines that were infected with 
retrovirus encoding TP53 (DN) or MEK1 (CA) and are more resistant to doxorubicin 
than FL/Doxo cells. This panel of cell lines displayed differences in the sensitivity to 
inhibitors that suppress mTORC1, BCL2/BCLXL, MEK1 or MDM2 activities, as well as, 
the proteasomal inhibitor MG132. The expression of key genes involved in cell growth 
and drug-resistance (e.g., MDM2, MDR1, BAX) also varied in these cells. Thus, we 
can begin to understand some of the key genes that are involved in the resistance of 
hematopoietic cells to chemotherapeutic drugs and targeted therapeutics.
INTRODUCTION
We have been investigating the roles of signal 
transduction pathways in chemotherapeutic drug- and 
radiation-resistance as well as sensitivity to small molecule 
inhibitors. The RAF/MEK/ERK and PI3K/PTEN/AKT/
mTORC1 pathways are central signal transduction 
pathways that are often activated in human cancers due to 
various mechanisms, including dysregulation of intrinsic 
components, as well as, mutations in upstream receptors 
and other interacting signaling molecules. These pathways 
are also regulated by other mechanisms including 
epigenetic mechanisms, post-translation modification and 
micro-RNAs (miRs) which alter the expression of key 
                                                             Research Paper
Oncotarget76526www.impactjournals.com/oncotarget
components as well as downstream effector molecules [1]. 
We have determined that some signaling pathways such as 
RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 
are critically involved in the sensitivity of various cancers 
such as; hematopoietic, breast, prostate and pancreatic to 
chemotherapy, radiotherapy and targeted therapy [2–8]. 
We determined that overexpression of 
constitutively-active or conditionally-active signaling 
molecules, (e.g., HA-RAS, RAF, MEK1, PI3K, AKT, 
GSK-3beta, ABL and BCR-ABL) and upstream growth 
factor receptors (e.g., epidermal growth factor receptor 
[EGFR] or insulin like growth factor receptor [IGF-1R] 
will alter the cytokine-dependency of hematopoietic or 
doxorubicin-sensitivity of breast or prostate cancer cells 
[7–12]. Introduction of phosphatase-deficient forms 
of PTEN or kinase-dead GSK-3beta will also alter the 
sensitivity of breast cancer cells to chemotherapeutic 
drugs and in some cases hormonal based therapies such 
as tamoxifen and targeted therapies such as rapamycin 
[5, 6, 10]. The RAF/MEK/ERK pathway will also induce 
the expression of cytokines and cytokine receptors which 
can alter the growth properties of cancer cells [8] and the 
drug- resistance of breast cancer cells [8–12]. The RAF/
MEK/ERK, PI3K/PTEN/AKT/mTORC1, EGFR, IGF-1R 
and other signaling pathways can also induce key proteins 
involved in regulation of cell cycle progression and 
resistance to chemotherapeutic drugs [13–25]. The RAF 
and PI3K pathways have also been linked with epithelial 
to mesenchymal (EMT) transition in breast cancer cell 
lines [10, 11]. 
TP53 is a critical transcription factor which is 
regulated by multiple mechanisms [19–21]. TP53 
is referred to as a tumor suppressor gene and it is 
frequently mutated and inactivated in human cancer. 
TP53 is also regulated by multiple mechanisms, including 
transcriptional, post-translational and microRNAs (miRs). 
TP53 also regulates the expression of multiple miRs, 
especially miR-34 which is a tumor suppressor miR. 
Previously we determined that TP53 was important in 
the drug-resistance of hematopoietic cells and involved 
in controlling the sensitivity of prostate cancer cells to 
chemotherapy as well as radiation therapy [22, 23]. 
 Anti-apoptotic proteins such as BCL2, BCLXL, 
MCL1, X-linked inhibitor of apoptosis (XIAP1) are also 
involved in drug-resistance [24–26]. Inhibitors to certain 
anti-apoptotic proteins have been developed [26]. Drug-
resistance proteins serve multiple roles, including efflux 
of xenobiotics as well as chemotherapeutic drugs. These 
proteins are also regulated by signaling cascades such 
as PI3K/PTEN/AKT/mTORC1 and RAF/MEK/ERK 
pathways [27–33]. There are also interactions between 
the RAF/MEK/ERK pathways and BCL2 proteins which 
can influence growth properties of hematopoietic and 
breast cancer cells [31–33]. Targeting signal transduction 
and apoptotic molecules is a therapeutic approach used 
in many cancers and cancer stem cells as well as in the 
suppression of aging [34–69]. 
The FL5.12 cell line represents a well-established 
interleukin-3 (IL-3) hematopoietic model which has 
been used to study key genes involved in hematopoietic 
and leukemia growth [70]. Previously we determined 
that the FL5.12 cell line was sensitive to doxorubicin 
[21]. Doxorubicin-resistant FL/Doxo cells were isolated 
from the parental FL5.12 cells by sub culturing the 
FL5.12 cells in 10 nM doxorubicin for three months 
[21]. FL/Doxo cells were also infected with retroviruses 
encoding dominant negative (DN) TP53 [TP53 (DN)] or 
constitutively-active MEK1 [MEK1 (CA)] [21]. These 
two modified FL/Doxo cell lines were more resistant 
to doxorubicin than the FL/Doxo cells from which 
they were derived. This panel of cells provides useful 
models to understand some of the effects of mutated 
genes on the sensitivity to chemotherapeutic drugs 
and signal transduction inhibitors. In this manuscript, 
we have compared the sensitivities of these cells to a 
series of signal transduction inhibitors which target the 
proteasome, the RAF/MEK/ERK, PI3K/PTEN/AKT/
mTORC1, TP53 (MDM2) pathways and BCL2/BCLXL 
anti-apoptotic proteins. Moreover, the effects of various 
targeted therapeutics were examined when they were 
combined with the chemotherapeutic drug doxorubicin 
or other small molecule inhibitors. 
RESULTS
Differential sensitivity to the proteasomal 
inhibitor MG132
The sensitivities of the FL5.12, FL/Doxo, FL/
Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) cells to 
the proteasomal inhibitor MG132 were determined. All 
the four different cell lines were examined the same day. 
The FL/Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) 
cells were more resistant to the proteasomal inhibitor 
MG-132 than the FL5.12 and FL/Doxo cells as IC50s of 
approximately 200 nM, 300 nM, 120 nM and 100 nM 
were observed, respectively. Introduction of the TP53 
(DN) gene increased the resistance of the FL/Doxo + 
TP53 (DN) cells approximately 1.7- to 2-fold compared 
to the FL5.12 and FL/Doxo cells respectively (Figure 1A). 
Introduction of the constitutively-active MEK1 (CA) gene 
increased the resistance of the FL/Doxo + MEK1 (CA) cells 
approximately 2.5- to 3-fold respectively compared to the 
FL5.12 and FL/Doxo cells (Figure 1A). Suppression of 
the proteasome by the proteasomal inhibitor results in the 
stabilization of TP53 WT [21]. Other studies have observed 
that proteasomal inhibition leads to increased TP53 nuclear 
levels and also results in induction of G1 arrest, apoptosis, 
and TP53-mediated gene expression (e.g., p21Cip1, PUMA, 
BAX) [71]. Cells which expressed TP53 (DN) or MEK1 
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(CA) were more resistant to the proteasomal inhibitor 
(Figure 1A) suggesting that the presence of the TP53 (DN) 
and MEK1 (CA) could abrogate some of the effects of 
the proteasomal inhibitor. Combining MG-132 and other 
proteasomal inhibitors with signal transduction inhibitors 
has been shown to be effective in inducing death in certain 
cancers [71–73]. 
Differential sensitivity to MDM2 inhibitor,  
nutlin-3a 
Nutlin-3a is a small molecule inhibitor that targets 
MDM2 [74, 75]. FL/Doxo cells were more sensitive to 
treatment with the nutlin-3a (IC50 = 1.5 μM) than either 
FL5.12 or FL/Doxo + TP53 (DN) cells (Figure 1B). 
Figure 1: Effects of the Proteasomal Inhibitor MG132 and MDM2 Inhibitor Nutlin-3a on FL5.12, FL/Doxo, FL/Doxo 
+ TP53 (DN) and FL/Doxo + MEK1 (CA) Cells. The effects of these inhibitors on: FL5.12 (solid red squares), FL/Doxo (solid blue 
upward triangles), FL/Doxo + TP53 (DN) (solid orange downward diamonds) and FL/Doxo + MEK1 (CA) (solid green diamonds) cells 
were determined by titrating all of the cells on the same day with: MG132 (Panel A) and Nutlin-3A (Panel B) inhibitors and then examined 
four days later by MTT analysis as described [21]. Arrows pointing to the X-axis indicate where the IC50 can be estimated. Statistical 
analysis (unpaired t test results) indicated that the two-tailed P values for FL/Doxo + MEK1(CA) and FL/Doxo + TP53 (DN) vs FL/Doxo 
in Panel A were less than 0.0001 which is considered to be extremely statistically significant. The two-tailed P value for FL5.12 vs FL/Doxo 
in Panel A equaled 0.0026 which is considered to be very statistically significant. In Panel B, the P value between the FL/Doxo + TP53 
(DN) and FL/Doxo was determined to be less than 0.0001 which is considered to be extremely highly significant. These experiments were 
performed four times with similar results.
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Approximately 5 µM nutlin-3a was required to reach the 
IC50 of the FL5.12 and FL/Doxo + TP53 (DN) cells. The FL/
Doxo + MEK1 (CA) cells were more sensitivity to nutlin-
3a as an IC50 of approximately 3 μM was observed. FL/
Doxo and FL/Doxo + MEK1 (CA) cells express functional 
TP53 [21]. Thus, the FL/Doxo cells were more sensitivity to 
agents which could alter TP53 or MDM2 activity. 
Differential sensitivity to mapk inhibitors 
The RAF/MEK/ERK pathway has been shown to be 
involved in the cytokine-dependency and drug resistance 
of various types of cells (e.g., breast, hematopoietic, 
liver, prostate and other cancers) [9, 12–14, 25, 76]. The 
effects of treatment of these cells with RAF, MEK or JNK 
inhibitors were examined (Figure 2). Sorafenib is a small 
molecule multi-kinase inhibitor which targets RAF, FLT3 
and cytokine-receptors [e.g., platelet derived growth factor 
receptor (PDGFR)] [74–79]. These cells were relatively 
resistant to the sorafenib inhibitor. Concentrations of 
greater than 5 μM sorafenib were required to reach the 
IC50 of FL/Doxo, FL/Doxo + MEK1 (CA) and FL/Doxo 
+ TP53 (DN) cells. An IC50 of approximately 5 μM was 
observed with FL5.12 cells (Figure 2A). 
In contrast, the FL/Doxo + MEK1 (CA) and FL/
Doxo + TP53 (DN) were more sensitive to the MEK1 
inhibitor PD0325901 than the FL5.12 and FL/Doxo cells 
(Figure 2B). IC50s of approximately 300 nM and 3,000 nM 
were observed with FL/Doxo + MEK1 (CA) and FL/Doxo 
+ TP53 (DN) cells, respectively, while concentrations of 
greater than 5 μM were required to reach the IC50 of FL/
Doxo and FL5.12 cells. Interestingly, introduction of the 
MEK1 (CA) into FL/Doxo cells [FL/Doxo + MEK1 (CA)] 
conferred sensitivity to the MEK inhibitor.
The effects of treatment with the JNK inhibitor 
SP600125 were examined. In general, all cells were 
not very sensitive to this inhibitor, as concentrations of 
greater than 5 μM were required to reach the IC50 with 
the exception of the FL/Doxo + TP53 (DN) cells where 
an IC50 of approximately 5 μM was observed (Figure 2C).
Figure 2: Effects of the Multi-Kinase Inhibitor Sorafenib, MEK1 (PD0325901) and JNK Inhibitors on FL5.12, FL/
Doxo, FL/Doxo + TP53 (DN) and FL/Doxo + MEK1(CA) Cells. The effects of these inhibitors on: FL5.12 (solid red squares), 
FL/Doxo (solid blue upward triangles), FL/Doxo + TP53 (DN) (solid orange downward diamonds) and FL/Doxo + MEK1 (CA) (solid 
green diamonds) cells were determined by titrating all of the cells on the same day with: Sorafenib (Panel A), PD0329501 (Panel B) 
and SP600125 (Panel C) inhibitors and then examined four days later by MTT analysis as described [21]. Arrows pointing to the X-axis 
indicate where the IC50 can be estimated. Statistical analysis (unpaired t test results) indicated that the two-tailed P values for FL/Doxo 
+ MEK1(CA) and FL/Doxo + TP53 (DN) vs FL/Doxo in Panel B was less than 0.0001 which is considered to be extremely statistically 
significant. These experiments were performed three times with similar results.
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Differential sensitivity to PI3K/AKT/mTORC1 
and BCL2/BCLXL inhibitors
We and others have also demonstrated that the 
PI3K/PTEN/AKT/mTORC1 pathway is involved in 
drug-resistance of various cancer types and abrogation 
of cytokine- dependence of hematopoietic cells [5, 
6, 10–12, 16, 20, 24, 27–30, 33, 35, 36, 38–41, 43–
55, 60, 63, 65, 67, 80–82]. The effects of targeting 
the PI3K/PTEN/Akt/mTORC1 pathway were also 
examined (Figure 3). Treatment of the cells with the 
PI3K inhibitor LY294002 resulted in the IC50s of 1,200 
nM, 1,200 nM, 500 nM and 500 nM for FL5.12, FL/
Doxo, FL/Doxo + TP53 (DN) or FL/Doxo + MEK1 
(CA) cells respectively (Figure 3A). Thus, the two lines 
that were more doxorubicin-resistant [FL/Doxo + TP53 
(DN) and FL/Doxo + MEK1 (CA)] were more sensitive 
than FL5.12 and FL/Doxo cells to the PI3K inhibitor, 
LY294002. 
The effects of treatment with the AKT inhibitor 
A443654 were examined. IC50s of 200 nM and 500 nM 
were observed with FL5.12 and FL/Doxo respectively. In 
contrast, greater than 500 nM A443654 were required to 
reach the IC50 of FL/Doxo + TP53 (DN) and FL/Doxo + 
MEK1 (CA) cells. 
The sensitivities of these cells to the mTORC1 blocker 
rapamycin were examined (Figure 3C). Interestingly, the 
FL/Doxo line was very sensitive to the mTORC1 blocker 
Figure 3: Effects of the PI3K Inhibitor LY294002, Akt Inhibitor A443654, mTORC1 blocker Rapamycin and BCL2 
Inhibitor ABT-737 on: FL5.12, FL/Doxo, FL/Doxo + TP53 (DN) and FL/Doxo + MEK1(CA) Cells. The effects of these 
inhibitors onFL5.12 (solid red squares), FL/Doxo (solid blue upward triangles), FL/Doxo + TP53 (DN) (solid orange downward diamonds) 
and FL/Doxo + MEK1(CA) (solid green diamonds) cells were determined by titrating all of the cells on the same day with: LY294002 
(Panel A), A443654 (Panel B), Rapamycin (Panel C) and ABT-737 (Panel D) inhibitors and then examined four days later by MTT analysis 
as described [21]. Arrows pointing to the X-axis indicate where the IC50 can be estimated.Statistical analysis (unpaired t test results) 
indicated that the two-tailed P values for FL5.12 or FL/Doxo vs either FL/Doxo + MEK1(CA) or FL/Doxo + TP53 (DN) in Panel A were 
0.0030 which is considered very statistically significant. In Panel B, the P values between FL5.12 and either FL/Doxo, FL/Doxo + TP53 
(DN), or FL/Doxo + MEK1 (CA) were determined to be less than 0.0001 which is considered to be extremely highly significant. In Panel 
C, the P value between FL/Doxo and FL/Doxo + MEK1 (CA) was determined to be less than 0.0001 which is considered to be extremely 
highly significant. In Panel D, the P value between FL/Doxo and FL5.12 was determined to be less than 0.0001 which is considered to be 
extremely highly significant. These experiments were performed three times with similar results.
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rapamycin and an IC50 of approximately 0.5 nM was 
observed (Figure 3C). An IC50 of approximately 15 nM 
rapamycin was observed with the FL/Doxo + MEK1(CA) 
cells. In contrast, the FL5.12 and FL/Doxo + TP53 (DN) 
cells were not as sensitive to rapamycin and the IC50 for these 
two lines was not reached with up to 500 nM doxorubicin. 
The FL/Doxo + TP53 (DN) cells were not very sensitive to 
rapamycin at these concentrations. These studies point to the 
importance of mTORC1 in the growth of the drug-resistant 
FL/Doxo cells and introduction of TP53 (DN) suppressed the 
effects of rapamycin on these cells. 
The sensitivities of the cells to the BCL2 inhibitor 
ABT-737 were determined (Figure 3D). Interestingly, 
the FL/Doxo cells were more sensitive to this inhibitor 
and an IC50 of approximately 55 nM was observed. In 
contrast, an IC50 of approximately 600 nM was observed 
with FL5.12 cells. The FL/Doxo + TP53 (DN) and FL/
Doxo + MEK1 (CA) cells were less sensitive to the ABT-
737 inhibitor. 
Combining MG-132 and doxorubicin to increase 
therapeutic effectiveness 
The effects of combining MG-132 with 
doxorubicin were examined (Figure 4A). The cells were 
also titrated for their sensitivity to doxorubicin in these 
same experiments. Doxorubicin IC50s of approximately 
10 nM, 25 nM, 100 nM and 300 nM were observed in 
these experiments with FL5.12, FL/Doxo, FL/Doxo + 
TP53 (DN) and FL/Doxo + MEK1 (CA) cells. Addition 
of the suboptimal dose of MG-132 (10 nM) reduced the 
IC50 for doxorubicin approximately 5-fold in FL5.12 cells 
to approximately 2 nM, >50-fold in FL/Doxo cells to < 
2 nM, 2.3-fold to 45 nM in FL/Doxo + TP53 (DN) and 
4.3-fold to 70 nM in FL/Doxo + MEK1 (CA) cells (Panel 
A). Thus, treatment with MG-132 reduced the resistance 
of the cells to doxorubicin, more significantly in the FL/
Doxo, FL5.12 and FL/Doxo + MEK1 (CA) cells than in 
FL/Doxo + TP53 (WT) cells. These experiments point 
to the importance of the proteasome in the sensitivity 
to doxorubicin, especially in the cells that were more 
sensitive to doxorubicin. Furthermore, the cells with 
TP53 (DN) were less sensitive to the combination of 
doxorubicin and MG-132.
Combining PD0325901 and doxorubicin to 
increase therapeutic effectiveness 
The effects of combining PD0325901 with 
doxorubicin were examined (Figure 4B). The cells were 
also titrated for their sensitivity to doxorubicin in these 
same experiments. Doxorubicin IC50s of approximately 
40 nM, 100 nM, 120 nM and 300 nM were observed in 
these experiments for: FL5.12, FL/Doxo, FL/Doxo + TP53 
(DN) and FL/Doxo + MEK1 (CA) cells. Addition of the 
suboptimal dose of PD0325901 (100 nM) reduced the IC50 
for doxorubicin approximately: 3.3-fold in FL5.12, 3-fold 
in FL/Doxo + MEK1 (CA) cells, and 1.5-fold FL/Doxo 
+ TP53 (DN) cells but not in FL/Doxo cells (Figure 4B). 
These experiments point to the importance of the MEK1 
in the sensitivity of FL5.12 and FL/Doxo + MEK1 (CA) 
cells to doxorubicin.
Combining rapamycin and doxorubicin to 
increase therapeutic effectiveness 
The effects of treatment of the cells with 
doxorubicin and a suboptimal does of rapamycin were 
determined (Figure 4C). The cells were also titrated 
for their sensitivity to doxorubicin in these same 
experiments. Doxorubicin IC50s of approximately: 12 
nM, 22 nM, 90 nM and 320 nM were observed in these 
experiments for FL5.12, FL/Doxo, FL/Doxo + TP53 
(DN) and FL/Doxo + MEK1 (CA) cells. Addition of 
a suboptimal dose of rapamycin (10 nM) reduced the 
IC50 for doxorubicin approximately 6-fold in FL5.12 
cells to approximately 2 nM, > 11-fold in FL/Doxo 
cells to < 2 nM, 2-fold to 42 nM in FL/Doxo + TP53 
(DN) and 80-fold in FL/Doxo + MEK1 (CA) cells to 
approximately 4 nM. Thus, treatment with rapamycin 
reduced the resistance of the cells to doxorubicin, more 
significantly in the FL/Doxo + MEK1 (CA) than FL/
Doxo or FL5.12 cells. There was only a 2-fold reduction 
in FL/Doxo + TP53 (WT) cells. These experiments 
point to the importance of the mTORC1 in sensitivity 
to doxorubicin and point to an important interaction 
between the MEK and mTORC1 pathways in drug-
resistance.
Combining nutlin-3a and doxorubicin to 
increase therapeutic effectiveness 
The effects of treatment of the cells with 
doxorubicin and a suboptimal dose of nutlin-3a were 
determined (Figure 4D). The cells were also titrated 
for their sensitivity to doxorubicin in these same 
experiments. Doxorubicin IC50s of approximately 12 nM, 
100 nM, 210 nM and 300 nM were observed in these 
experiments for FL5.12, FL/Doxo, FL/Doxo + TP53 
(DN) and FL/Doxo + MEK1 (CA) cells. Addition of the 
suboptimal dose of nutlin-3a (500 nM) reduced the IC50 
for doxorubicin approximately: 6-fold in FL5.12 cells to 
< 2 nM, 50-fold in FL/Doxo cells to < 2 nM and 5-fold to 
42 nM in FL/Doxo + TP53 (DN) and 75-fold in FL/Doxo 
+ MEK1 (CA) cells to 4 nM. Thus, treatment with nutlin-
3a reduced the resistance of the cells to doxorubicin, 
more significantly in the FL/Doxo + MEK1 (CA), FL/
Doxo and FL5.12 cells than in cells containing DN TP53 
gene. However, these results also demonstrated that in 
the FL/Doxo + TP53 (DN) that still have endogenous 
WT TP53 genes, there is some sensitivity to the nutlin-3a 
MDM2 inhibitor.
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Combining ABT-737 and doxorubicin or the 
PI3K inhibitor LY294002 to increase therapeutic 
effectiveness 
The effects of combining ABT-737 with doxorubicin 
were examined (Figure 5). The cells were also titrated for 
their sensitivity to doxorubicin in these same experiments. 
Doxorubicin IC50s of approximately: 15 nM, 60 nM, 90 nM 
and 300 nM were observed in these experiments for FL5.12, 
FL/Doxo, FL/Doxo + TP53 (DN) and FL/Doxo + MEK1 
(CA) cells. Addition of the suboptimal dose of ABT-737 (50 
nM) reduced the IC50 for doxorubicin approximately, 30-fold 
in FL/Doxo, 4-fold FL/Doxo + TP53 (DN) cells and 100-fold 
in FL/Doxo + MEK1 (CA) cells (Figure 5A).
The effects of combining a suboptimal dose of 
doxorubicin with ABT-737 were also determined (Figure 
5B). The suboptimal dose of doxorubicin reduced the 
IC50 for ABT-737 in all four cell lines ranging from 
approximately 12 nM in FL/Doxo + MEK1 (CA) to 30 
nM in FL/Doxo and FL5.12 cells and to 90 nM in FL/
Doxo + TP53 (DN) cells (Figure 5B). These experiments 
point to the importance of the BCL2/BCLXL in the 
sensitivity of all the cells to doxorubicin. Furthermore, 
these experiments demonstrate that while the FL/Doxo 
+ MEK1 (CA) cells were not very sensitive to treatment 
with the BCL2 inhibitor by itself (Figure 3D), but when 
the BCL2 inhibitor was combined with doxorubicin, the 
FL/Doxo + MEK1 (CA) cells become very sensitive.
Figure 4: Effects of Different Doses of Doxorubicin in Combination with Suboptimal Constant Doses of MG-132, 
PD0325901, Rapamycin and Nutlin-3a on: FL5.12, FL/Doxo, FL/Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) Cells. 
The effects of these inhibitors onFL5.12 (solid red squares), FL/Doxo (solid blue upward triangles), FL/Doxo + TP53 (DN) (solid orange 
downward diamonds) and FL/Doxo + MEK1(CA) (solid green diamonds) cells were determined by titrating all of the cells on the same 
day with doxorubicin and suboptimal doses of 10 nM MG132 (Panel A), 500 nM PD0325901 (Panel B), 10 nM Rapamycin (Panel C) and 
500 nM Nutlin-3a (Panel D) inhibitors and then examined four days later by MTT analysis as described [21]. Arrows pointing to the X-axis 
indicate where the IC50 can be estimated. Statistical analysis (unpaired t test results) indicated that the two-tailed P values for FL5.12 
or FL/Doxo vs either FL/Doxo + MEK1(CA) or FL/Doxo + TP53 (DN) in Panel A were less than 0.0001 which is considered extremely 
statistically significant. In Panel B, the P values between FL5.12 and either FL/Doxo, FL/Doxo + TP53 (DN), or FL/Doxo + MEK1 (CA) 
were determined to be less than 0.0001 which is considered to be extremely highly significant. In Panel C, the P values between FL/Doxo + 
TP53 or FL/Doxo + MEK1 (CA) vs FL5.12 or FL/Doxo weredetermined to be less than 0.0001 which is considered to be extremely highly 
significant. In Panel D, the P values between FL5.12 vs FL/Doxo, FL/Doxo + TP53 (DN) or FL/Doxo + MEK1 (CA) were determined to be 
less than 0.0001 which is considered to be extremely highly significant.These experiments were performed four times with similar results.
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The effects of combining BCL2 and the PI3K 
inhibitor (LY294002) were also determined. Different 
concentrations of LY294002 were combined with a 
suboptimal dose of ABT-737 (50 nM) in these experiments 
(Figure 5C). Addition of a suboptimal dose of ABT-737 
lowered the amount of relative growth in FL/Doxo, 
FL/Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA). 
However, the slopes of the dose response lines did not 
really change.
The effects of different concentrations of ABT-
737 and a constant dose of 500 nM LY294002 was 
determined (Figure 5D). Addition of the suboptimal 
dose of LY294002 reduced the IC50 for ABT-737 
approximately 2.2-fold in FL/Doxo cells and >10-
fold in FL/Doxo + TP53 (DN) and FL/Doxo + MEK1 
(CA) cells. In contrast, addition of the suboptimal dose 
of LY294002 did not reduce the IC50 for ABT-737 in 
FL5.12 cells.
Figure 5: Effects of different doses of ABT-737 in combination with Doxorubicin or the PI3K Inhibitor LY294002. 
The effects of these inhibitors on: FL5.12 (solid red squares), FL/Doxo (solid blue upward triangles), FL/Doxo + TP53 (DN) (solid 
orange downward diamonds) and FL/Doxo + MEK1(CA) (solid green diamonds) cells were determined by titrating all of the cells with 
doxorubicin on the same day and a suboptimal dose of 500 nM ABT-737 (Panel A), or ABT-737 and a suboptimal dose of 5 nM doxorubicin 
and then examined four days later by MTT analysis as described [21]. The effects of LY294002 or ABT-737 inhibitors on: FL5.12 (solid red 
squares), FL/Doxo (solid blue upward triangles), FL/Doxo + TP53 (DN) (solid orange downward diamonds) and FL/Doxo + MEK1(CA) 
(solid green diamonds) cells were determined by titrating all of the cells on the same day with LY294002 and a suboptimal dose of 500 
nM ABT-737 (Panel C), or ABT-737 and a suboptimal dose of 500 nM LY294002 (Panel D). Arrows pointing to the X-axis indicate where 
the IC50 can be estimated. Statistical analysis (unpaired t test results) indicated that the two-tailed P values for FL5.12 or FL/Doxo + TP53 
(DN) vs FL/Doxo or FL/Doxo + MEK1 (CA) in Panel A were 0.0001 which is considered extremely statistically significant. In Panel B, 
the P values between FL/Doxo + TP53 (DN) vs FL5.12, FL/Doxo or FL/Doxo + MEK1 (CA) were determined to be less than 0.0001 
which is considered to be extremely highly significant. In this same panel, the P values between FL5.12 or FL/Doxo vs FL/Doxo +MEK1 
(CA) were determined to equal 0.0002 which is considered to be extremely statistically significant. In Panel C, the P values between 
FL5.12 vs FL/Doxo, FL/Doxo + TP53 (DN) or FL/Doxo + MEK1 (CA) were determined to be less than 0.0001 which is considered to be 
extremely highly significant. In Panel D, the P values between FL5.12 vs FL/Doxo, FL/Doxo + MEK1 (CA) or FL/Doxo + TP53 (DN) 
were determined to be less than 0.0001 which is considered to be extremely highly significant. In this same panel, the P values between FL/
Doxo vs FL/Doxo + MEK1 (CA) or FL/Doxo + TP53 (DN) were determined to equal 0.0009 which is considered to be extremely highly 
significant. These experiments were performed three-times with similar results.
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Combining ABT-737 and PD0325901 to increase 
therapeutic effectiveness 
The effects of combining ABT-737 and a suboptimal 
dose of PD0325901 were examined (Figure 6A). Addition 
of the suboptimal dose of PD0325901 (500 nM) reduced 
the IC50 for ABT-737 greater than 50-fold in FL/Doxo + 
MEK1 (CA) cells and approximately 1.7-fold in FL/Doxo 
+TP53 (DN) and 1.5-fold in FL/Doxo cells but did not 
reduce the IC50 for doxorubicin in FL5.12 cells.
Figure 6: Effects of different doses of ABT-737 or PD0325901 in combination with suboptimal constant doses of 
PD0325901 or ABT-737. The effects of these inhibitors on:FL5.12 (solid red squares), FL/Doxo (solid blue upward triangles), FL/Doxo 
+ TP53 (DN) (solid orange downward diamonds) and FL/Doxo + MEK1(CA) (solid green diamonds) cells were determined by titrating 
all of the cells on the same day with ABT-737 and a suboptimal dose of 500 nM PD0329501 (Panel A), or PD0325901 and a suboptimal 
dose of 500 nM ABT-737 and then examined four days later by MTT analysis as described [21]. Arrows pointing to the X-axis indicate 
where the IC50 can be estimated. Statistical analysis (unpaired t test results) indicated that the two-tailed P values for FL5.12 or FL/Doxo 
+ TP53 (DN) vs either FL/Doxo or FL/Doxo + MEK1(CA) in Panel A were less 0.0001 than which is considered extremely statistically 
significant. In Panel B, the P values between FL/Doxo or FL5.12 and FL/Doxo + MEK1 (CA) were determined to be less than 0.0001 which 
is considered to be extremely highly significant. These experiments were performed three-times with similar results.
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The effects of combining PD0325901 and a 
suboptimal dose of ABT-737 were examined (Figure 6B). 
Addition of the suboptimal dose of ABT-737 (50 nM) 
reduced the IC50 for PD0325901 greater than 400-fold in 
FL/Doxo cells and approximately 67-fold in FL5.12 cells. 
In contrast, this combination of PD0325901 and ABT-
737 did not lower the IC50 for PD0325901 in either FL/
Doxo + MEK1(CA) or FL/Doxo + TP53 (DN) suggesting 
that further reduction of BCL2/BCLXL activity did not 
increase the sensitivity of these two lines to the MEK1 
inhibitor.
Combining rapamycin and either MG132 or 
nutlin-3a to increase therapeutic effectiveness 
The effects of treatment of the cells with rapamycin 
and a suboptimal does of MG132 were determined (Figure 
7A). Addition of the suboptimal dose of MG132 (10 nM) 
reduced the IC50 for rapamycin > 500-fold in FL5.12 cells 
to approximately 0.5 nM, > 2-fold in FL/Doxo cells to < 
2 nM. The addition of MG132 had less effects on the IC50 
for rapamycin in FL/Doxo + TP53 (DN) and FL/Doxo + 
MEK1 (CA) cells.
The effects of treatment of the cells with rapamycin 
and a suboptimal dose of nutlin-3a were determined 
(Figure 7B). Addition of the suboptimal dose of nutlin-
3a (500 nM) reduced the IC50 for rapamycin 28-fold in 
FL5.12 cells to approximately 18 nM, > 2-fold in FL/
Doxo cells to < 2 nM. The addition of nutlin-3a reduced 
the IC50 for rapamycin approximately 10-fold to 1 nM in 
FL/Doxo + MEK1 (CA) cells and had some effects on the 
IC50 for rapamycin in FL/Doxo + TP53 (DN). Thus, the 
mTORC pathway is important in the drug resistance of 
these hematopoietic cells.
Expression of TP53 and signaling proteins in 
FL5.12, FL/Doxo, FL/Doxo + TP53 (WT) and 
FL/Doxo + MEK1 (CA) cells
Previously, we determined that when FL5.12 were 
deprived of the required cytokine IL-3 for 24 hrs., they 
express TP53 which can be stabilized after treatment with 
the proteasomal inhibitor MG132 [21]. The levels of TP53 
can be increased in these cells upon treatment with 100 
and 1,000 nM doxorubicin. In contrast, FL/Doxo cells did 
not express as much TP53 when they are deprived of IL-3 
for 24 hours. However, up addition of 100 or 1,000 nM 
doxorubicin, there were increases in the levels of TP53 
detected [21]. 
In the present studies, we determined that no 
detectable levels of BIM were observed in FL5.12 cells 
when they were deprived of IL-3 and then treated with 
doxorubicin or doxorubicin and the MG132 proteasomal 
inhibitor (Figure 8). In contrast, BIM was detected in FL/
Doxo cells when they were IL3-deprived and then treated 
with doxorubicin but not when they were treated with 
MG132 and greater than 10 nM doxorubicin, indicated 
that suppression of the proteasome was inhibiting the 
expression of BIM in response to doxorubicin treatment. 
The expression of MCL1 was upregulated upon 
treatment with 100 and 1,000 nM doxorubicin of 
FL5.12 cells but not FL/Doxo cells. Treatment with 10 
μM MG132 by itself resulted in the detection of MCL1 
in FL5.12 cells but not FL/Doxo cells. The expression 
of MCL1 was suppressed by the proteasomal inhibitor 
(MG132) in the presence of doxorubicin in FL5.12 cells. 
In contrast, the expression of MCL1 was not detected in 
the FL/Doxo cells in either the presence or absence of 
MG132 and doxorubicin. 
Very low levels of MDM2 were detected in FL5.12 
cells, even in the presence of MG132. The FL/Doxo cells 
were determined to express higher levels of MDM-2 than 
FL5.12 cells (Figure 8). In contrast to the expression of 
BIM in FL/Doxo cells, the levels of MDM2 tended to 
increase slightly in FL/Doxo cells when they were treated 
with doxorubicin and MG132. These results suggest that 
there was more MDM2 activity in FL/Doxo cells than 
FL5.12 cells.
The expression of phospho-JNK was detected in 
FL5.12 cells when they were treated with MG132 and 
either low or no doxorubicin. In contrast, phospho-JNK 
(P-JNK) was not detected in FL5.12 cells when they were 
cultured in absence of MG132. No P-JNK was detected in 
FL/Doxo cells in the presence and absence of doxorubicin 
and MG132. BAX, which is a TP53-regulated gene, was 
detected in both FL5.12 and FL/Doxo cells. The levels of 
total and activated ERK and TP53 in FL5.12 and FL/Doxo 
cells in these same gels were presented previously [21].
The levels of BIM, MCL1, TP53, P-JNK, BAX and 
ERK1,2 were examined in FL/Doxo + TP53 (DN) and FL/
Doxo+MEK1 (CA) cells (Figure 8). The FL/Doxo+MEK1 
(CA) cells did not express BIM, MCL1 or P-JNK upon 
treatment with doxorubicin, MG132, or combined doses 
of doxorubicin and MG132 treatment as determined by 
western blot analysis. The FL/Doxo+TP53 (DN) cells, that 
contained the TP53 (DN) retrovirus, expressed high levels 
of TP53 protein as it was stabilized by the introduced 
truncation in the gene. The FL/Doxo + MEK1 (CA) cells 
expressed similar levels of TP53 as the FL/Doxo cells 
[21]. The FL/Doxo + TP53 [DN] cells expressed low to 
undetectable levels of the TP53-inducible gene BAX, 
suggesting that TP53 (DN) suppressed its expression. 
BAX expression was detected in FL/Doxo + MEK1(CA) 
cells. The levels of total ERK1,2 are presented as a loading 
control.
Effects of doxorubicin and inhibitors on gene 
expression 
We examined the expression of some of these and 
other genes in the presence and absence of doxorubicin 
by qRT-PCR (Figures 9–12). In addition, the effects of 
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the MEK (PD0329051), BCL2 (ABT-737), mTORC1 
(rapamycin) and MDM2 (nutlin-3a) inhibitors on the 
expression of key genes were examined by qRT-PCR. 
The levels of gene expression were normalized to the 
levels of 18S rRNA molecules detected (Figures 9–12). 
We summarize the key differences in gene expression as 
determined by qRT-PCR between FL5.12, FL/Doxo, FL/
Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) cells.
Figure 7: Effects of Different Doses of Rapamycin in Combination with Suboptimal Constant Doses of MG-132 or 
Nutlin-3a. The effects of these inhibitors on: FL5.12 (solid red squares), FL/Doxo (solid blue upward triangles), FL/Doxo + TP53 (DN) 
(solid orange downward diamonds) and FL/Doxo + MEK1(CA) (solid green diamonds) cells were determined by titrating all of the cells 
on the same day with rapamycin and a suboptimal dose of 10 nM MG132 (Panel A), or a suboptimal dose of 500 nM Nutlin-3a and then 
examined four days later by MTT analysis as described [21]. Arrows pointing to the X-axis indicate where the IC50 can be estimated. 
Statistical analysis (unpaired t test results) indicated that the two-tailed P values for FL5.12 or FL/Doxo vs FL/Doxo + MEK1(CA) in Panel 
A were less than 0.0001 which are considered extremely statistically significant. In Panel B, the P values between FL/Doxo + TP53 (DN) vs 
FL5.12, FL/Doxo FL/Doxo + MEK1 (CA) were determined to be less than 0.0001 which are considered to be extremely highly significant. 
These experiments were performed three-times with similar results.
Oncotarget76536www.impactjournals.com/oncotarget
Higher levels of MDR1 are detected in 
doxorubicin-resistant cells 
Doxorubicin-sensitive FL5.12 cells expressed low 
levels of mRNA transcripts encoding MDR1, less than 
2 copies (1.91) per million 18S rRNAs (Figure 9). The 
effects of treatment with the MEK, BCL2, MEK + BCL2, 
rapamycin and nutlin-3a inhibitors were examined. The 
biggest decrease in expression of MDR1 (3.1-fold) was 
observed when FL5.12 cells were treated with both MEK 
+ BCL2 inhibitors as 0.6 copies of MDR1 were detected 
per million 18S rRNAs. Treatment with the MEK, BCL2, 
rapamycin or nutlin-3a inhibitors resulted in less than a 
2-fold decreases in MDR1 mRNA levels.
The effects of doxorubicin treatment on MDR1 
expression in FL5.12 cells were examined. Treatment 
with doxorubicin resulted in a 3.8-fold decrease in MDR1 
mRNAs as 0.61 copies of MDR1 mRNA per million 18S 
rRNA molecules were observed. In general, treatment with 
the MEK, rapamycin or nutlin-3a inhibitors did not result 
Figure 8: Western blot Analysis of Apoptotic Regulatory Gene Expression, MDM2 and Activated JNK in FL5.12, 
FL/Doxo,FL/Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) Cells. The effects of treatment with different concentrations 
of doxorubicin in the absence and presence of 10 µM MG132 was determined as described [21]. The western blots were probed with 
antibodies to the indicated proteins. * = presence of TP53 (DN) protein.
Oncotarget76537www.impactjournals.com/oncotarget
in a dramatic decrease in MDR1 levels as between 0.52 to 
0.63 MDR1 mRNAs per million 18S rRNA molecule were 
detected. In contrast, when FL5.12 cells were treated with 
doxorubicin and the BCL2 inhibitor or the combination 
of MEK and BCL2 inhibitors, more MDR1 mRNA 
transcripts were seen (0.91, 1.15 copies respectively) than 
when the FL5.12 cells treated with doxorubicin by itself. 
Thus, treatment with the BCL2 inhibitor in the presence of 
doxorubicin resulted in an approximate to 1.8- to 2.3-fold 
increase in MDR1 mRNA levels.
Doxorubicin-resistant FL/Doxo cells expressed 
3.5-fold higher levels of MDR1, (7.17 copies per million 
18S rRNAs), than FL5.12 cells (1.91 copies of MDR1 per 
million 18S rRNA molecules) (Figures 9 and 10). The 
levels of these MDR1 transcripts did not appear to be 
affected by treatment with MEK, BCL2, MEK + BCL2, 
rapamycin or nutlin-3a treatment when FL/Doxo cells 
were cultured in the presence of IL-3 and no doxorubicin 
(5.98 to 6.63 copies of MDR1 per million 18S rRNAs). 
The levels of MDR1 transcripts decreased 1.8-fold 
when FL/Doxo cells were cultured in the presence of IL-3 
and doxorubicin (4.28 copies) compared to when the cells 
were cultured in IL-3 (7.17 copies). When the FL/Doxo 
cells were treated with the MEK, BCL2, rapamycin and 
nutlin-3a inhibitors, there were less than 2-fold increase 
in MDR1 mRNA transcript levels (1.1- to 1.5- fold). The 
levels of MDR1 increased approximately 2-fold when 
FL/Doxo cells were cultured in the presence of MEK + 
BCL2 inhibitors. Thus, the combination of MEK + BCL2 
inhibitors and doxorubicin treatment resulted in more 
MDR1 mRNA transcripts in both FL5.12 and FL/Doxo 
cells. 
The expression of MDR1 was also examined in FL/
Doxo + TP53 (DN) cells (Figure 12). When FL/Doxo 
+ TP53 cells were cultured in the presence of IL-3 and 
no inhibitors, approximately 20 copies of MDR1 were 
observed per million 18S rRNA molecules. The levels 
of MDR1 decreased to approximately 15 copies per 
million 18S rRNA molecules when the cells were treated 
with MEK + BCL2 inhibitors, rapamycin or nutlin-3A 
inhibitors. 
When FL/Doxo + TP53 (DN) cells were cultured 
in the presence of IL-3 + doxorubicin and no inhibitors, 
approximately 13 copies of MDR1 were observed per 
million 18S rRNA molecules. The levels of MDR1 
remained around 12–20 copies per million 18S rRNA 
molecules when the cells were treated with the inhibitors. 
Higher levels of MDR1 transcripts were observed 
in the FL/Doxo + MEK1(CA) cells. Approximately 
40 copies of MDR1 were detected in the FL/Doxo + 
MEK1(CA) cells when they were cultured with IL-3 
and the various inhibitors (Figure 11). Approximately 50 
copies of MDR1 per million 18S rRNA molecule were 
detected when the cells were cultured in the presence of 
Figure 9: qRT-PCR Analysis of Gene Expression in FL5.12 cells. (Panels A and B) Cells were treated with IL-3 for 24 hours. 
(Panels C and D) Cells were treated with IL-3 + 25 nM doxorubicin for 24 hours. The cells were treated with the indicated inhibitors (MEK 
inhibitor, PD0325901 = 5,000 nM, BCL2 inhibitor ABT-737 = 1000 nM, MEK + BCL2 inhibitors 5,000 nM PD0325901 + 1,000 nM ABT-
737 or rapamycin = 100 nM) for 24 hours in medium containing IL-3 and the presence or absence of 25 nM doxorubicin.
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IL-3 and doxorubicin. FL/Doxo + MEK1(CA) cells are the 
most resistant cells to doxorubicin [21]. The highest levels 
of MDR1 RNA transcripts were seen in these cells. 
Higher levels of MCL1 expression in 
doxorubicin-sensitive FL5.12 cells 
The levels of the anti-apoptotic MCL1 mRNA 
transcripts were determined when FL5.12 cells were 
cultured in the presence and absence of doxorubicin 
and the signal transduction inhibitors (Figure 9). 
Approximately 19 copies of MCL1 mRNA transcripts per 
million 18S rRNA transcripts were detected with FL5.12 
cells were cultured in the presence of IL-3. The MCL1 
mRNA levels decreased to approximately 7 copies when 
FL5.12 cells were cultured in the presence of IL-3 and the 
combination of MEK + BCL2 inhibitor or the nutlin-3a 
inhibitor. 11 copies of MCL1 mRNA were seen when they 
were cultured with rapamycin. 
Approximately 13 copies of MCL1 mRNA 
were detected when FL5.12 cells were cultured in the 
presence of IL-3 + doxorubicin. Treatment of the cells 
with the MEK, MEK + BCL2, rapamycin or nutlin-3a 
inhibitors further reduced the levels of MCL1 detected 
to approximately 6–7 copies per million 18S rRNA 
molecules. 
Approximately 16 copies of MCL1 mRNA per 
million 18S rRNA molecules were observed in FL/Doxo 
cells when they were cultured with IL-3 (Figure 10). 
Treatment of the cells with the MEK, MEK + BCL2, 
rapamycin or nutlin-3a inhibitors reduced the levels of 
MCL1 to approximately 8 copies per million 18S rRNA 
molecules. 
When FL/Doxo cells were cultured in the presence 
of IL-3 + doxorubicin, approximately 14 copies of 
MCL-1 were detected. Upon treatment of the cells 
with doxorubicin and the MEK, BCL2, MEK + BCL2, 
rapamycin or nutlin-3a inhibitors approximately 8–10 
copies of BCL2 were observed per million 18S rRNA 
molecule.
Interestingly lower levels of MCL1 mRNA 
transcripts were detected in FL/Doxo + TP53 (DN) 
and FL/Doxo + MEK1 (CA) cells (Figures 11 and 12). 
Approximately 10 copies of MCL1 mRNA per million 
18S rRNA transcripts were observed in FL/Doxo + TP53 
(DN) when they were cultured in the presence of IL-3. 
The expression of MCL1 did not vary significantly when 
the cells were treated with MEK, BCL2 or rapamycin 
inhibitors. There was a slight drop to approximately 6 
transcripts when the cells were cultured in the presence 
of MEK + BCL2 inhibitors and to 5.5 transcripts when 
they were cultured with nutlin-3a. When FL/Doxo + 
Figure 10: qRT-PCR Analysis of Gene Expression in FL/Doxo cells. (Panels A and B) Cells were treated with IL-3 for 24 hours. 
(Panels C and D) Cells were treated with IL-3 + 25 nM doxorubicin for 24 hours. The cells were treated with the indicated inhibitors (MEK 
inhibitor, PD0325901 = 5,000 nM, BCL2 inhibitor ABT-737 = 1000 nM, MEK + BCL2 inhibitors 5,000 nM PD0325901 + 1,000 nM ABT-
737 or rapamycin = 100 nM) for 24 hours in medium containing IL-3 and the presence or absence of 25 nM doxorubicin.
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TP53 (DN) were cultured with IL-3 and doxorubicin, 
approximately 9 copies of MCL1 were detected when the 
cells were cultured either in the absence or presence of 
BCL2, rapamycin or nutlin-3a inhibitors. Treatment with 
the MEK or MEK + BCL2 inhibitors reduced the levels to 
approximately 6–7 copies of MCL1 per million 18S rRNA 
molecules. 
Approximately 10 copies of MCL1 mRNA per 
million 18S rRNA transcripts were detected in FL/Doxo 
+ MEK1 (Act) when they were cultured in the presence 
of IL-3 (Figure 12). The expression of MCL1 varied 
less than 2-fold when the cells were treated with the 
MEK, BCL2 or rapamycin inhibitors. There was a slight 
drop to approximately 6 transcripts when the cells were 
cultured in the presence of MEK + BCL2 or nutlin-3a 
inhibitors. When FL/Doxo + MEK1 (Act) were cultured 
with IL-3 and doxorubicin, approximately 7–11 copies 
of MCL1 were observed even when the cells were 
cultured either in the absence or presence of MEK, 
BCL2, rapamycin or nutlin-3a inhibitors. Treatment 
with the MEK + BCL2 inhibitors reduced the levels 
to approximately 6 copies of MCL1 per million 18S 
rRNA molecules. Thus, the FL5.12 and FL/Doxo cells 
displayed higher levels of MCL1 mRNA transcripts 
than the FL/Doxo + TP53 (DN) and FL/Doxo + 
MEK1(CA) cells. 
Higher levels of BCL2 expression in 
doxorubicin-sensitive FL5.12 cells 
The levels of the anti-apoptotic BCL2 mRNA 
transcripts were determined when FL5.12 cells were 
cultured in the presence and absence of doxorubicin 
and the signal transduction inhibitors (Figure 9). 
Approximately 20 copies of BCL2 mRNA transcripts 
per million 18S rRNA transcripts were detected with 
FL5.12 cells were cultured in the presence of IL-3. 
The BCL2 levels decreased to approximately 11 copies 
when FL5.12 cells were cultured in the presence of the 
MEK inhibitor and 6–7 copies in the combination of 
MEK + BCL2 inhibitors, rapamycin or the nutlin-3A 
inhibitors and 11 copies when they were cultured with 
rapamycin. 
When FL5.12 cells were cultured in the presence 
of IL-3 and doxorubicin, approximately 11 copies of 
BCL2 were observed. When the cells were cultured in the 
presence of MEK, MEK + BCL2, rapamycin or nutlin-
3a inhibitors approximately 5–8 copies of BCL2 were 
detected per million 18S rRNA molecules.
Approximately 7 copies of BCL2 per million 18S 
rRNA molecules were seen in FL/Doxo cells when they 
were cultured with IL-3 (Figure 10). Treatment of the cells 
with the MEK, BCL2, MEK + BCL2, rapamycin or nutlin-
Figure 11: qRT-PCR Analysis of Gene Expression in FL/Doxo + TP53 (DN) cells. (Panels A and B) Cells were treated with 
IL-3 for 24 hours. (Panels C and D) Cells were treated with IL-3 + 25 nM doxorubicin for 24 hours. The cells were treated with the indicated 
inhibitors (MEK inhibitor, PD0325901 = 5,000 nM, BCL2 inhibitor ABT-737 = 1000 nM, MEK + BCL2 inhibitors 5,000 nM PD0325901 
+ 1,000 nM ABT-737 or rapamycin = 100 nM) for 24 hours in medium containing IL-3 and the presence or absence of 25 nM doxorubicin.
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3a inhibitors reduced the levels of BCL2 to approximately 
4 copies per million 18S rRNA molecules. 
When FL/Doxo cells were cultured in the presence 
of IL-3 and doxorubicin, approximately 7 copies of 
BCL2 were detected. When the cells were cultured in the 
presence of MEK, BCL-2, MEK + BCL2, rapamycin or 
nutlin-3a inhibitors approximately 4–5 copies of BCL-2 
were observed per million 18S rRNA molecules.
Approximately 10 copies of BCL2 mRNA 
transcripts per million 18S rRNA transcripts were 
detected in FL/Doxo + TP53 (DN) cells were cultured 
in the presence of IL-3 (Figure 11). The BCL-2 levels 
decreased to approximately 6 copies when FL/Doxo + 
TP53 (DN) cells were cultured in the presence of the MEK 
inhibitor and 4 copies in the combination of MEK + BCL2 
inhibitors or rapamycin or the nutlin-3a inhibitor. 
When FL/Doxo + TP53 (DN) cells were cultured 
in the presence of IL-3 and doxorubicin, approximately 
8 copies of BCL2 were detected. When the cells were 
cultured in the presence of MEK, MEK + BCL2, rapamycin 
or nutlin-3a inhibitors, approximately 4–6 copies of BCL2 
were observed per million 18S rRNA molecules.
Approximately 5 copies of BCL2 per million 
18S rRNA molecules were detected in FL/Doxo + 
MEK1 (CA) cells when they were cultured with IL-3 
(Figure 12). Treatment of the cells with the MEK, BCL2, 
MEK + BCL2, rapamycin or nutlin-3A inhibitors reduced 
the levels of BCL2 to approximately 2–3 copies per 
million 18S rRNA molecules. 
When FL/Doxo + MEK1(CA) cells were cultured 
in the presence of IL-3 and doxorubicin, approximately 
5 copies of BCL2 were detected. When the cells were 
cultured in the presence of MEK, MEK + BCL2, 
rapamycin approximately 2–3 copies of BCL2 were 
observed per million 18S rRNA molecules.
Higher levels of BIM expression in doxorubicin-
sensitive FL5.12 cells 
The levels of the pro-apoptotic BIM mRNA 
transcripts were determined when FL5.12 cells were 
cultured in the presence and absence of doxorubicin 
and the signal transduction inhibitors (Figure 9). 
Approximately 25 copies of BIM mRNA transcripts per 
million 18S rRNA transcripts were detected when FL5.12 
cells were cultured in the presence of IL-3. The BIM 
levels increased to approximately 42 copies when FL5.12 
cells were cultured in the presence of the MEK inhibitor 
and 32 copies in the BCL2 inhibitor treated cells. When 
the FL5.12 cells were cultured in combination of MEK 
Figure 12: qRT-PCR analysis of gene expression in FL/Doxo + MEK1 (CA) cells. (Panels A and B) Cells were treated with 
IL-3 for 24 hours. (Panels C and D) Cells were treated with IL-3 + 25 nM doxorubicin for 24 hours. The cells were treated with the indicated 
inhibitors (MEK inhibitor, PD0325901 = 5,000 nM, BCL2 inhibitor ABT-737 = 1000 nM, MEK + BCL2 inhibitors 5,000 nM PD0325901 
+ 1,000 nM ABT-737 or rapamycin = 100 nM) for 24 hours in medium containing IL-3 and the presence or absence of 25 nM doxorubicin.
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+ BCL2 inhibitors, rapamycin or the nutlin-3A inhibitor, 
approximately 20 copies of BIM mRNA per million 18S 
rRNA molecules were observed. 
When FL/Doxo cells were cultured in the presence 
of IL-3 and doxorubicin, approximately 8 copies of BIM 
were detected (Figure 10). When the cells were cultured 
in the presence of MEK, BCL2, rapamycin or nutlin-
3a approximately 8–9 copies of BIM were detected per 
million 18S rRNA molecules. When FL/Doxo cells were 
cultured with the MEK + BCL2 combined inhibitor 
treatment, approximately 11 copies of BIM were seen.
Approximately 10 copies of BIM per million 18S 
rRNA molecules were detected in FLDoxo cells when 
they were cultured with IL-3. Treatment of the cells with 
the MEK, BCL2, MEK + BCL2, rapamycin or nutlin-3A 
inhibitors did not significantly alter the levels of BIM 
mRNA transcripts seen. 
Approximately 10 copies of BIM mRNA transcripts 
per million 18S rRNA transcripts were detected in FL/
Doxo + TP53 (DN) cells when they were cultured in the 
presence of IL-3. The BIM levels remained relatively 
constant when FL/Doxo + TP53 (DN) cells were cultured 
in the presence of the MEK, rapamycin or nutlin-3A 
inhibitors (7–9 copies). 
When FL/Doxo + TP53 (DN) cells were cultured in 
the presence of IL-3 and doxorubicin, approximately 11 
copies of BCL2 were observed (Figure 11). When the cells 
were cultured in the presence of MEK, MEK + BCL2, 
rapamycin or nutlin-3a inhibitors approximately 10 copies 
of BIM were detected per million 18S rRNA molecules. 
The levels of BIM seen in the BCL2 inhibitor-treated FL/
Doxo + TP53 (DN) cells cultured in doxorubicin increased 
slightly to approximately 14 copies per million 18S rRNA 
molecules.
Approximately 5 copies of BIM per million 18S 
rRNA molecules were detected in FL/Doxo + MEK1 
(CA) cells when they were cultured with IL-3 (Figure 12). 
Treatment of the cells with the MEK, BCL2, MEK + 
BCL2, rapamycin or nutlin-3A inhibitors did not alter the 
levels of BIM detected. 
When FL/Doxo + MEK1(CA) cells were cultured 
in the presence of IL-3 and doxorubicin, approximately 
6 copies of BIM were observed. When the cells were 
cultured in the presence of MEK, BCL2, MEK + BCL2 
inhibitors, approximately 9–10 copies of BCL2 were seen 
per million 18S rRNA molecules. In contrast, rapamycin 
treatment did not alter the levels of BIM detected 
compared to the cells treated with no inhibitor.
Relatively constant levels of Foxo3a detected 
after doxorubicin or inhibitor treatment 
The levels of the Foxo3a mRNA transcripts were 
determined when the cells were cultured in the presence 
and absence of doxorubicin and the signal transduction 
inhibitors. Approximately 62 copies of Foxo3a mRNA 
transcripts per million 18S rRNA transcripts were detected 
when FL5.12 cells were cultured in the presence of IL-3 
(Figure 9). The Foxo3a levels increased to approximately 
75 copies when FL5.12 cells were cultured in the presence 
of the MEK inhibitor and 69 copies in the presence of the 
BCL2 inhibitor. When the FL5.12 cells were cultured in 
combination of MEK + BCL2 inhibitors or rapamycin, 
48–51 copies of Foxo-3a were detected. When the cells 
were cultured with the nutlin-3A inhibitor approximately 
64 copies of Foxo-3a per million 18S rRNA molecules 
were observed. 
When FL5.12 cells were cultured in the presence 
of IL-3 and doxorubicin, approximately 40 copies of 
Foxo-3a were detected. When the cells were cultured in 
the presence of MEK, BCL2, or rapamycin inhibitors 
approximately 41–48 copies of Foxo-3a were detected 
per million 18S rRNA molecules. The nutlin-3a inhibitor 
treatment resulted in an increase of Foxo-3a transcripts to 
65 copies per million rRNA molecules.
Approximately 48 copies of Foxo-3a per million 
18S rRNA molecules were detected in FL/Doxo cells when 
they were cultured with IL-3 (Figure 10). Treatment of the 
cells with the MEK, BCL2, MEK + BCL2, rapamycin or 
nutlin-3A inhibitors resulted in a range of Foxo-3a mRNA 
transcripts from 34 transcripts with the BCL2 inhibitor to 
60 transcripts with the nutlin-3a inhibitor. 
When FL/Doxo cells were cultured in the presence 
of IL-3 and doxorubicin, approximately 35 copies of 
Foxo-3a were detected. When the cells were cultured in 
the presence of MEK or BCL2 inhibitors, approximately 
37–40 transcripts were detected. 60 Foxo-3a transcripts 
were observed upon the combined MEK and BCL2 
inhibitor treatment, 56 after rapamycin and 53 after nutlin-
3a treatment.
Approximately 39 copies of Foxo-3a mRNA 
transcripts per million 18S rRNA transcripts were 
detected in FL/Doxo + TP53 (DN) cells were cultured in 
the presence of IL-3 (Figure 11). The levels of Foxo-3a 
mRNA transcripts increased to 52, 56, 45, 47 and 49 after 
MEK, BCL2, MEK + BCL2, rapamycin and nutlin-3a 
treatment respectively.
When FL/Doxo + TP53 (DN) cells were cultured in the 
presence of IL-3 and doxorubicin, approximately 40 copies 
of Foxo-3a were detected. When the cells were cultured in 
the presence of MEK, BCL2, MEK + BCL2, rapamycin or 
nutlin-3a approximately 45, 55, 45, 52 and 47 copies of Foxo-
3a were observed per million 18S rRNA molecules. 
Approximately 27 copies of Foxo-3a per million 
18S rRNA molecules were detected in FL/Doxo + MEK1 
(CA) cells when they were cultured with IL-3 (Figure 12). 
Treatment of the cells with the MEK, BCL2, MEK + 
BCL2, rapamycin or nutlin3A inhibitors did not alter the 
levels of Foxo-3a as 28, 32, 32 and 37 transcripts were 
observed respectively. 
When FL/Doxo + MEK1(CA) cells were cultured 
in the presence of IL-3 and doxorubicin, approximately 
Oncotarget76542www.impactjournals.com/oncotarget
51 copies of Foxo-3a were detected. When the cells were 
cultured in the presence of MEK, BCL2, MEK + BCL2, 
rapamycin and nutlin-3a inhibitors approximately 50, 73, 
70, 54 and 64 copies of Foxo-3a were detected per million 
18S rRNA molecules. 
BAX mRNA levels are decreased in FL/Doxo + 
TP53 (DN) and FL/Doxo+MEK1(CA) cells
The levels of BAX mRNA transcripts were 
determined when the cells were cultured in the presence 
and absence of doxorubicin and the signal transduction 
inhibitors. Approximately 76 copies of BAX mRNA 
transcripts per million 18S rRNA transcripts were detected 
when FL5.12 cells were cultured in the presence of IL-3 
(Figure 9). The BAX levels decreased to approximately 69 
copies when FL5.12 cells were cultured in the presence of 
the MEK inhibitor and 62 copies in the BCL2 inhibitor. 
When the FL5.12 cells were cultured in combination 
of MEK + BCL2, rapamycin or nutlin-3A inhibitors, 
approximately 48 copies of BAX were observed. 
When FL5.12 cells were cultured in the presence 
of IL-3 and doxorubicin, approximately 52 copies of 
BAX were detected. When the cells were cultured in the 
presence of the MEK inhibitor, 35 copies were observed. 
66 copies of BAX mRNA transcripts were seen when the 
cells were cultured in the presence of the BCL2 inhibitor. 
57 copies of BAX mRNA transcripts were seen when cells 
were cultured with both MEK and BCL2 inhibitors, 54 
and 52 copies were detected when the cells were cultured 
with rapamycin or nutlin-3A inhibitors, respectively. 
Approximately 86 copies of BAX per million 18S 
rRNA molecules were detected in FL/Doxo cells when 
they were cultured with IL-3 (Figure 10). Treatment of 
the cells with the MEK, BCL2, MEK + BCL2, rapamycin 
or nutlin-3A inhibitors resulted in a range of BAX mRNA 
transcripts from 46–56 with 46 BAX transcripts observed 
with the MEK + BCL2 inhibitor to 56 transcripts when the 
cells were treated with rapamycin. 
When FL/Doxo cells were cultured in the presence 
of IL-3 and doxorubicin, approximately 63 copies of 
BAX were detected. When the cells were cultured in the 
presence of MEK or BCL2 inhibitors, approximately 63 
transcripts were observed. 57 BAX transcripts were seen 
upon the combined MEK + BCL2 inhibitor or rapamycin 
treatment and 60 BAX mRNA transcripts after nutlin-3a 
treatment. 
The TP53 (DN) gene suppressed BAX expression. 
Approximately 22 copies of BAX mRNA transcripts per 
million 18S rRNA transcripts were detected when FL/
Doxo + TP53 (DN) cells were cultured in the presence of 
IL-3 (Figure 11). The levels of BAX mRNA transcripts 
increased to 22, 24, 16, 23 and 26 after MEK, BCL2, MEK 
+ BCL2, rapamycin and nutlin-3a treatment respectively.
When FL/Doxo + TP53 (DN) cells were cultured 
in the presence of IL-3 and doxorubicin, approximately 
24 copies of BAX were observed (Figure 12). When the 
cells were cultured in the presence of MEK, BCL2, MEK 
+ BCL2, rapamycin or nutlin-3a approximately 21, 19, 17, 
25 and 26 copies of BAX were detected per million 18S 
rRNA molecules. 
Approximately 30 copies of BAX per million 18S 
rRNA molecules were detected in FL/Doxo + MEK1 
(CA) cells when they were cultured with IL-3 (Figure 12). 
Treatment of the cells with the MEK, BCL2, rapamycin 
or nutlin-3A inhibitors did not alter the levels of BAX 
mRNA transcripts as 30–32 transcripts were observed. 23 
BAX mRNA transcripts were observed in the combined 
treatment with MEK + BCL2 inhibitors. 
When FL/Doxo + MEK1(CA) cells were cultured 
in the presence of IL-3 and doxorubicin, approximately 
30 copies of BAX were detected. When the cells were 
cultured in the presence of MEK, BCL2, MEK + BCL2 
and rapamycin inhibitors, approximately 28, 28, 24 and 32 
copies of BAX mRNA transcripts were seen respectively 
per million 18S rRNA molecules. When the cells were 
cultured in IL-3 and doxorubicin and nutlin-3, 38 copies 
of BAX mRNA transcripts were detected.
In summary, the expression of BAX mRNAs was 
sensitive to inhibitor treatments in FL5.12 and FL/Doxo 
cells when they were cultured in IL-3. The detection of 
BAX mRNA transcripts were lower in the FL/Doxo + 
TP53(DN) and FL/Doxo + MEK1(CA) cells. The nutlin-
3A treatment resulted in increased BAX mRNA levels as 
38 copies of BAX were detected when the FL/Doxo + 
MEK1(CA) cells were cultured in the presence of IL-3, 
doxorubicin and nutlin-3a, while only 30 copies of BAX 
were detected when the FL/Doxo + MEK1(CA) cells 
were cultured in the presence of IL-3 and nutlin-3a, BAX 
mRNA transcripts were inhibited by TP53 (DN) in FL/
Doxo + TP53 (DN) cells.
YY1 mRNA levels are elevated in FL5.12 cells 
YY1 is an important transcription factor implicated in 
many cancers and drug resistance [83, 84]. The expression 
of YY1 is regulated by TP53 and miR-34 [85–87]. The 
levels of YY1 mRNA transcripts were determined when 
the cells were cultured in the presence and absence 
of doxorubicin and the signal transduction inhibitors. 
Approximately 94 copies of YY1 mRNA transcripts per 
million 18S rRNA transcripts were detected with FL5.12 
cells were cultured in the presence of IL-3 (Figure 9). The 
YY1 mRNA levels decreased slightly to approximately 77 
copies when FL5.12 cells were cultured in the presence 
of the MEK inhibitor and 62 copies in the presence of the 
BCL2 inhibitor. When the FL5.12 cells were cultured in 
combination of MEK + BCL2 inhibitors, rapamycin or 
nutlin-3A, approximately 54, 47 and 44 copies of YY1 
mRNA transcripts were observed. Thus, the expression 
of YY1 mRNA was suppressed when FL5.12 cells were 
cultured with certain inhibitors in the presence of IL-3. 
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When FL5.12 cells were cultured in the presence of 
IL-3 and doxorubicin, approximately 52 copies of YY1 
mRNA transcripts were detected. When FL5.12 cells were 
cultured in the presence of the MEK inhibitor, 37 copies 
were observed. 54 copies of YY1 were detected when the 
cells were cultured in the presence of the BCL2 inhibitor. 
54 copies of YY1 were seen when FL5.12 cells were 
cultured with both MEK and BCL2 inhibitors, 28 and 25 
copies were detected when the FL5.12 cells were cultured 
with rapamycin or nutlin-3A, respectively. 
Approximately 43 copies of YY1 per million 18S 
rRNA molecules were detected in FL/Doxo cells when 
they were cultured with IL-3 (Figure 10). Treatment of 
the cells with the MEK, BCL2, MEK + BCL2, rapamycin 
or nutlin-3A inhibitors resulted in a range of YY1 mRNA 
transcripts from 27 to 38 transcripts with 38, 29, 27, 35 
and 27 transcripts respectively. 
When FL/Doxo cells were cultured in the presence 
of IL-3 and doxorubicin, approximately 32 copies of 
YY1 were detected. When the cells were cultured in the 
presence of MEK inhibitor, 35 copies were observed and 
42 copies were seen in the presence of the BCL2 inhibitor. 
Approximately 36, 36 and 31 YY1 mRNA transcripts were 
detected upon the combined MEK + BCL2 inhibitors, 
rapamycin and nutlin-3A inhibitor treatments respectively.
Approximately 21 copies of YY1 mRNA transcripts 
per million 18S rRNA transcripts were detected in FL/
Doxo + TP53 (DN) cells when they were cultured in the 
presence of IL-3 (Figure 11). The levels of YY mRNA 
transcripts were: 21, 24, 16, 14 and 16 after MEK, 
BCL2, MEK + BCL2, rapamycin and nutlin-3a inhibitor 
treatments, respectively.
When FL/Doxo + TP53 (DN) cells were cultured in 
the presence of IL-3 and doxorubicin, approximately 21 
copies of YY1 were detected (Figure 11). When the cells 
were cultured in the presence of MEK, BCL2, MEK + 
BCL2, rapamycin or nutlin-3a inhibitors, approximately 
19, 17, 18, 21 and 20 copies of YY1 were seen per million 
18S rRNA molecules respectively. 
Approximately 16 copies of YY1 per million 18S 
rRNA molecules were detected in FL/Doxo + MEK1 
(CA) cells when they were cultured with IL-3 (Figure 
12). Treatment of the cells with the MEK, BCL2, MEK 
+ BCL2, rapamycin or nutlin-3A inhibitors altered the 
levels of YY1 slightly as 14–20 transcripts were observed 
(17, 20, 14, 16 and 14 respectively). 
When FL/Doxo + MEK1(CA) cells were cultured 
in the presence of IL-3 and doxorubicin, approximately 
18 copies of YY1 were detected. When the cells were 
cultured in the presence of MEK, BCL2, MEK + BCL2, 
rapamycin and nutlin-3A inhibitors approximately 18, 17, 
15, 18, and 17 copies of YY1 were observed respectively 
per million 18S rRNA molecules. The expression of YY1 
mRNA was higher in FL5.12 cells than in doxorubicin-
resistant cells. The more drug resistant cells, FL/Doxo 
+ TP53 (DN) and FL/Doxo + MEK1(CA) expressed 
less YY1 transcripts than FL/Doxo cells which in turn 
expressed less YY1 transcripts than FL5.12 cells. 
BCLXL mRNA levels are elevated in FL5.12 
cells 
The levels of BCLXL mRNA transcripts were 
determined when FL5.12 cells were cultured in the 
presence and absence of doxorubicin and the signal 
transduction inhibitors (Figure 9). Approximately 145 
copies of BCLXL mRNA transcripts per million 18S 
rRNA transcripts were detected with FL5.12 cells were 
cultured in the presence of IL-3 and 150 when the cells 
were cultured in the presence of IL-3 and the BCL2 
inhibitor. The BCLXL levels decreased to approximately 
72 copies when FL5.12 cells were cultured in the presence 
of the MEK inhibitor. When the FL5.12 cells were cultured 
in combination of MEK + BCL2 inhibitors, rapamycin or 
nutlin-3a, approximately 48, 64 and 61 copies of BCLXL 
mRNAs per million 18S rRNA transcripts were observed. 
Thus, the expression of BCLXL mRNAs was suppressed 
when FL5.12 cells were cultured with certain inhibitors in 
the presence of IL-3. The MEK inhibitor had the greatest 
suppressive effect on BCLXL mRNAs.
When FL5.12 cells were cultured in the presence 
of IL-3 and doxorubicin, approximately 88 copies of 
BCLXL were detected (Figure 9). When the cells were 
cultured in the presence of the MEK inhibitor, 51 copies 
were seen. 102 copies of BCLXL mRNA transcripts were 
seen when the cells were cultured in the presence of the 
BCL2 inhibitor. 50 copies of BCLXL mRNA transcripts 
were detected when cells were cultured with both MEK 
and BCL2 inhibitors, 44 and 54 copies of BCLXL mRNA 
transcripts were observed when the cells were cultured 
with rapamycin or nutlin-3A respectively. 
Approximately 98 copies of BCLXL per million 18S 
rRNA molecules were detected in FL/Doxo cells when 
they were cultured with IL-3 (Figure 10). Treatment of 
the cells with the MEK, BCL2, MEK + BCL2, rapamycin 
or nutlin-3a inhibitors resulted in a range of BCLXL 
mRNA transcripts from 54 to 73 transcripts with 62, 73, 
64, 54 and 73 respectively. Rapamycin had the largest 
suppressive effect on BCLXL mRNAs in FL/Doxo cells 
cultured in the presence of IL-3.
When FL/Doxo cells were cultured in the presence 
of IL-3 and doxorubicin, approximately 73 copies of 
BCLXL mRNA transcripts were detected. When the cells 
were cultured in the presence of the MEK inhibitor, 53 
copies were detected and 48 copies were observed in the 
presence of the BCL2 inhibitor. Approximately, 125, 57 
and 56 BCLXL mRNA transcripts were observed upon 
the combined MEK and BCL2 inhibitor, rapamycin and 
nutlin-3a treatment, respectively.
Approximately 38 copies of BCLXL mRNA 
transcripts per million 18S rRNA transcripts were detected 
in FL/Doxo + TP53 (DN) cells, when they were cultured 
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in the presence of IL-3 (Figure 11). The levels of BCLXL 
mRNA transcripts were: 32, 53, 23, 28 and 40 after MEK, 
BCL2, MEK + BCL2, rapamycin and nutlin-3a treatment 
respectively.
When FL/Doxo + TP53 (DN) cells were cultured 
in the presence of IL-3 and doxorubicin, approximately 
42 copies of BCLXL were detected. When the cells were 
cultured in the presence of MEK, BCL2, MEK + BCL2, 
rapamycin or nutlin-3a inhibitors, approximately 30, 48, 
29, 32 and 34 copies of BCLXL mRNAs were observed 
per million 18S rRNA molecules. 
Approximately 31 copies of BCLXL mRNA per 
million 18S rRNA molecules were detected in FL/Doxo 
+ MEK1 (CA) cells when they were cultured with IL-3 
(Figure 12). Treatment of the cells with the MEK, BCL2, 
MEK + BCL2, rapamycin or nutlin-3A inhibitors altered 
the levels of BCLXL as 19–33 transcripts were observed 
(19, 33, 22, 21 and 28) respectively. 
When FL/Doxo + MEK1 (CA) cells were cultured 
in the presence of IL-3 and doxorubicin, approximately 
61 copies of BCLXL were detected. When the cells were 
cultured in the presence of MEK, BCL2, MEK + BCL2, 
rapamycin and nutlin-3a inhibitors approximately 34, 74, 
38, 34, and 41 copies of BCLXL mRNA transcripts were 
observed respectively per million 18S rRNA molecules. 
Treatment of FL/Doxo + MEK1 (CA) cells with BCL2 
inhibitor prevented the decrease in BCLXL mRNA levels 
observed in the other inhibitor and IL-3 and doxorubicin 
treated cells. 
The expression of BCLXL mRNA was in general 
higher in FL5.12 cells than in doxorubicin-resistant 
cells. The MEK1 inhibitor suppressed BCLXL mRNA 
levels. An exception was with FL/Doxo cells treated with 
doxorubicin and both the MEK + BCL2 inhibitors.
MRP1 mRNA levels are elevated in FL5.12 
cells 
The levels of MRP1 mRNA transcripts were 
determined when FL5.12 cells were cultured in the presence 
and absence of doxorubicin and the signal transduction 
inhibitors (Figure 9). Approximately 211 copies of MRP1 
mRNA transcripts per million 18S rRNA transcripts were 
detected when FL5.12 cells were cultured in the presence of 
IL-3 and 225 when the cells were cultured in the presence of 
IL-3 and the BCL2 inhibitor. The MRP1 levels decreased to 
approximately 186 copies when FL5.12 cells were cultured 
in the presence of the MEK inhibitor. When the FL5.12 cells 
were cultured in combination of MEK + BCL2 inhibitors, 
rapamycin or nutlin-3a approximately, 116, 96 and 93 
copies of MRP1 mRNAs per million 18S rRNA transcripts 
were observed. Thus, the expression of MRP1 mRNA was 
suppressed when FL5.12 cells were cultured with certain 
inhibitors in the presence of IL-3. 
When FL5.12 cells were cultured in the presence 
of IL-3 and doxorubicin, approximately 143 copies of 
MRP1 were detected. When the cells were cultured in 
the presence of the MEK inhibitor, 106 copies were 
detected. 156 copies of MRP1 mRNA transcripts were 
seen when the cells were cultured in the presence of the 
BCL2 inhibitor. 112 copies of MRP1 mRNA transcripts 
were observed when cells were cultured with both MEK 
and BCL2 inhibitors. 98 and 108 copies of MRP1 mRNA 
transcripts were detected when the cells were cultured 
with rapamycin or nutlin-3a respectively. 
Approximately 249 copies of MRP1 per million 18S 
rRNA molecules were detected in FL/Doxo cells when 
they were cultured with IL-3 (Figure 10). Treatment of the 
cells with the MEK, BCL2, MEK + BCL2, rapamycin or 
nutlin-3a inhibitors resulted in a range of MRP1 mRNA 
transcripts from 178 to 212 transcripts with 212, 190, 
194, 178 and 192 respectively. Rapamycin had the largest 
suppressive effect on MRP1 mRNAs in FL/Doxo cells 
cultured in the presence of IL-3.
When FL/Doxo cells were cultured in the presence 
of IL-3 and doxorubicin, approximately 181 copies of 
MRP1 mRNA transcripts were detected. When the cells 
were cultured in the presence of MEK inhibitor, 197 
copies were observed and 185 copies were detected in 
the presence of the BCL2 inhibitor. Approximately 226, 
200 and 196 MRP1 mRNA transcripts were seen upon 
the combined MEK and BCL2 inhibitor, rapamycin and 
nutlin-3a treatment.
Approximately 107 copies of MRP1 mRNA 
transcripts per million 18S rRNA transcripts were detected 
when FL/Doxo + TP53 (DN) cells were cultured in the 
presence of IL-3. The levels of MRP1 mRNA transcripts 
were: 111, 133, 93, 100 and 89 after MEK, BCL2, MEK 
+ BCL2, rapamycin and nutlin-3a inhibitor treatment 
respectively.
When FL/Doxo + TP53 (DN) cells were cultured 
in the presence of IL-3 and doxorubicin, approximately 
107 copies of MRP1 were detected (Figure 10). When the 
cells were cultured in the presence of MEK, BCL2, MEK 
+ BCL2, rapamycin or nutlin-3a inhibitor, approximately 
108, 125, 90, 114 and 110 copies of MRP1 were observed 
per million 18S rRNA molecule. 
Approximately 118 copies of MRP1 per million 18S 
rRNA molecules were detected in FL/Doxo + MEK1 (CA) 
cells when they were cultured with IL-3. Treatment of the 
cells with the MEK, BCL2, MEK + BCL2, rapamycin 
or nutlin-3a inhibitors only slightly altered the levels of 
MRP1 mRNAs as 92–109 transcripts were observed (108, 
93, 92, 96 and 109 respectively). 
When FL/Doxo + MEK1 (CA) cells were cultured 
in the presence of IL-3 and doxorubicin, approximately 
174 copies of MRP1 were detected (Figure 12). When 
the cells were cultured in the presence of MEK, BCL2, 
MEK + BCL2, rapamycin and nutlin-3a inhibitors, 
approximately 176, 250, 168, 148, and 173 copies of 
MRP1 mRNA transcripts were observed respectively per 
million 18S rRNA molecules. The expression of MRP1 
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mRNA was higher in FL5.12 and FL/Doxo cells than in 
FL/Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) cells. 
Addition of doxorubicin and the BCL2 inhibitor resulted 
in higher levels of expression of MRP1 mRNAs in FL/
Doxo + MEK1 (CA) cells.
Levels of beta-2 microglobulin detected
 As a control, the levels of beta-2 microglobulin 
were also examined in all cells and treatment conditions. 
The levels of beta-2 microglobulin were relatively constant 
within an individual cell line in the different culture (−/+ 
doxorubicin) and inhibitor treatments.
Effects of doxorubicin on YY1 protein expression
The effects of doxorubicin on FL5.12, FL/Doxo 
and FL/Doxo + TP53 (DN) were determined by western 
blot analysis (Figure 13). Cells were deprived of IL-3 
for 24 hours and then treated with the presence of IL-3 
in the presence and absence doxorubicin and MEK 
or mTORC1 inhibitors. The levels of the expression 
of activated ERK1,2 were examined as controls. 
Low levels of YY1 were detected in doxorubicin-
sensitive FL5.12 cells, however approximately 10-
fold higher levels of YY1 protein were detected when 
the doxorubicin-sensitive cells were also treated with 
doxorubicin.
Low levels of YY1 protein were detected in both 
the FL/Doxo and FL/Doxo + TP53 (DN) cells. The levels 
of YY1 increased approximately 2-fold in FL/Doxo cells 
when they were treated with both IL-3 and doxorubicin. In 
contrast, the levels of YY1 protein did not increase as much 
in FL/Doxo + TP53 (DN) when they were treated with the 
combination of IL-3 and doxorubicin, less than 2-fold. 
The levels of the YY1 protein did not appear to be 
sensitive to treatment with either the MEK or mTORC1 
inhibitor rapamycin. In contrast, the levels of activated 
ERK1,2 were sensitive to the MEK inhibitor but did not 
decrease after treatment with the mTORC1 inhibitor. 
The levels of activated ERK1,2 actually increased in the 
rapamycin treated FL5.12, FL/Doxo and FL/Doxo + TP53 
(DN) cells. This may have resulted from the feedback loop 
on ERK1,2 which is elicited by mTORC1 suppression. 
As a loading control, the levels of total ERK were also 
monitored in these cells. 
DISCUSSION
In our studies, we have investigated the sensitivities 
of a parental and three doxorubicin-resistant derivative 
cell lines to various targeted therapeutics, either alone 
Figure 13: Western blot Analysis of YY1 Expression after IL-3 or IL-3 + Doxorubicin Treatment in FL5.12, FL/Doxo 
and FL/Doxo + TP53 (DN) Cells. Cells were deprived of IL-3 for 24 hours and then treated with nothing, 5,000 nM PD0325901 MEK 
inhibitor or IL-3 + 100 nM rapamycin mTORC1 blocker for 30 minutes, then the cells were stimulated with either IL-3 or IL-3 + 25 nM 
doxorubicin for 30 minutes and then cell lysates were prepared and western blot analysis performed as described [21].
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or in combination with doxorubicin. Some of the effects 
that certain of these targeted therapeutics have on gene 
expression was also examined in the panel of cells in the 
presence and absence of doxorubicin. An overview of 
where some of these signal transduction inhibitors and 
doxorubicin interact with signaling and TP53 pathways is 
presented in Figure 14. 
TP53 is critical in induction of apoptosis, 
chemotherapeutic drug resistance, aging as well as the 
responses to target therapy [87–96]. TP53 can regulate 
various micro-RNAs (miRs) which are important in drug-
resistance in various cancers [87, 97, 98]. The regulation 
of autophagy by TP53 and other factors is important in 
chemotherapeutic drug- resistance [99].
The cells which were more drug-resistant, FL/Doxo 
+ TP53 (DN) and FL/Doxo + MEK1(CA) cells were more 
resistant to the proteasomal inhibitor MG-132 than either 
the FL5.12 or FL/Doxo + MEK1 (CA) cells (Figure 1A) 
where are more drug-sensitive than either of the more 
drug-resistant cells. Inhibition of the proteasome would be 
predicted to stabilize TP53. This could result in increased 
TP53 activity and chemosensitization [100]. 
Proteasomal inhibitors may be combined with 
certain drugs to increase the effectiveness of acute 
Figure 14: Overview of signal transduction pathways and signaling molecules examined in this study.
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myeloid leukemia (AML) therapy [101]. Inhibition of the 
proteasome increased the effectiveness of volasertib and in 
inducing mitotic arrest and prolonged patient survival [102]. 
One of the consequences of doxorubicin treatment of 
certain cancer cell types such as breast cancer and others 
is the induction of NF-kappaB. Indeed in our studies, we 
observed that doxorubicin increased the levels of YY1 
expression which is an NF-kappa-B-responsive gene 
[84–87]. Certain second generation proteasomal inhibitors 
such as carfilzomib will suppress NF-kappaB activity 
and prevent doxorubicin and proteasomal inhibitor-
resistance. One of the molecules induced by doxorubicin 
and carfilzomib treatment is JNK while one of the events 
suppressed by the treatment is IkappaBalpha degradation. 
Carfilzomib treatment overcomes bortezomib-resistance 
of certain breast cancer cells. Thus, the proteasomal 
inhibitor carfilzomib may sensitize breast cancer cells to 
doxorubicin [103]. 
Interestingly, the doxorubicin-sensitive cell line, FL/
Doxo was more sensitive to the MDM2 inhibitor nutlin-
3a, than the parent or drug-resistant FL/Doxo + TP53 
(DN) and FL/Doxo + MEK1 (CA) cells (Figure 1B). 
Various additional novels approaches are being used to 
target MDM-2 [104]. In addition, the targeting of mutant 
TP53 is being examined, including clinically trials [105].
At the concentrations used, the multi-kinase 
inhibitor sorafenib did not appear to have significant 
effects of any of the four cell lines (Figure 2A). The effects 
of sorafenib on drug resistance of various cancer types 
have been examined, such as hepatocellular carcinoma 
(HCC) [106–111]. 
Not surprisingly, the FL/Doxo + MEK1(CA) cells 
were the most sensitive to the MEK1 inhibitor (Figure 
2B). The FL/Doxo + TP53 (DN) were more sensitive to 
the MEK1 inhibitor than either FL5.12 or FL/Doxo cells. 
Thus, the more doxorubicin-resistant cells [FL/Doxo 
+ MEK1 (CA) and FL/Doxo + TP53 (DN) cells were 
more sensitive to the MEK1 inhibitor than the cells that 
were not as drug-resistant. In general, the four cell lines 
were not very sensitive to the JNK inhibitor SP600125 
(Figure 2C), although the FL/Doxo + MEK1 (CA) cells 
were more sensitive than the three other cell lines. This 
may have resulted between a cross-talk between JNK and 
MEK signaling in these cells. Interactions between the 
RAF/MEK/ERK and JNK signaling pathways have been 
previously reported [88]. 
JNK signaling is involved in the drug-resistance of 
many cancers including HCC [112, 113]. The JNK signaling 
pathway is important in the development and progression of 
colorectal cancer and other cancer types [114]. 
The JNK pathway has been investigated in AML and 
has been determined to be the effector pathway in response 
to certain drug treatments [115]. The JNK pathway is 
also critical in pancreatic cancer stem cells (CSC) as 
suppression of JNK signaling renders the pancreatic 
CSC sensitive to TNF-related apoptosis-inducing ligand 
(TRAIL) [116]. JNK regulates Foxo-3a in certain cancer 
types such as lung adenocarcinoma [117]. 
The RAF/MEK/ERK pathway is also involved in 
the drug resistance of various cancers [9, 13, 14, 20, 21, 
42]. Various inhibitors, in different combinations, have 
been shown to influence chemotherapeutic drug-resistance 
which may occur by altering signaling cross-talk [32]. 
The RAF/MEK/ERK and other signaling pathways may 
be targeted in certain cancers in the absence of obvious 
activated or inactivated oncogenes [14, 15]. 
The protein phosphatase 2A (PP2A) interacts 
with the RAF/MEK/ERK and other signaling pathways. 
Suppression of PP2A activity has been associated with 
poor patient outcome with certain breast cancer patients 
as well as doxorubicin resistance [118]. An additional 
phosphatase, dual-specificity phosphatase 2 (DUSP2) also 
regulates the RAF/MEK/ERK pathway. Hypoxia inducible 
factor-1 alpha (HIF1-alpha) has been shown to induce 
lapatinib-resistance in HER2-postive breast cancers by 
deregulating DUSP2 activity [119]. Protein phosphatases 
often function as tumor suppressor proteins [65, 69]. 
Targeting of the RAF/MEK/ERK, PI3K/PTEN/
AKT/mTORC1, SRC or other signaling pathways has 
shown promise in anti-cancer therapy [42]. Targeting 
MEK (and downstream ERK) with PD0325901 has been 
shown to enhance the ability of the PI3K inhibitor NVP-
BKM-120 in lung cancer cells. NVP-BKM-120 induces 
ERK activation and autophagy. Suppression of ERK 
activation resulted in increased therapeutic effectiveness 
against the lung cancer cells [120]. The effectiveness of 
PD0325901 has been examined in cells which proliferate 
in response to mutant HRAS and was determined to be 
effective in suppressing growth, especially in combination 
with mTOR inhibitors [121]. Combining PD0325901 and 
SRC inhibitors suppressed tumor growth and induced 
mesenchymal to epithelial transition in non-small cell lung 
cancer cells [122]. 
The effects of the PI3K inhibitor were more 
significant on the more drug-resistant cells as the IC50s for 
LY294002 were higher in FL5.12 and FL/Doxo cells than 
in FL/Doxo + MEK1 (CA) and FL/Doxo + TP53 (DN) 
cells (Figure 3A). Thus, the degree of drug-resistance 
was correlated with sensitivity to the PI3K inhibitor, 
LY294002. The concept of targeting MEK and PI3K is 
being examined in many cancers including those that are 
drug-resistant [42, 123]. 
The PI3K/PTEN/AKT/mTORC1 pathway is 
dysregulated in multiple cancers including leukemia 
and multiple solid cancers. Often components of this 
and related phospholipid signaling pathways are tumor 
suppressors [124, 125]. Multiple components of the 
PI3K/PTEN/AKT/mTORC1 pathway have and are being 
considered for potential targeting in human cancer, e.g., 
p70S6K in breast cancer [126], as well as, obesity [127]. 
Certain PI3K inhibitors are being investigated in 
drug-resistance hematopoietic and other cancer types 
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and are showing promising effects [53, 54, 128–131]. 
Combining PI3K/mTOR and other pathway inhibitors 
or glucocorticoids may be an approach to overcome the 
therapeutic-resistance of certain cancers [132–134]. 
Targeting the PI3K and androgen receptor pathways may 
be an approach to treat therapy-resistant prostate cancer 
[135, 136].
The doxorubicin-sensitive FL5.12 cells were 
more sensitive to the AKT inhibitor A443654 than the 
doxorubicin-resistant FL/Doxo, FL/Doxo + MEK1 (CA) 
and FL/Doxo + TP53 (DN) cells (Figure 3B). AKT has 
been examined as a therapeutic target in various leukemia 
and other cell types [43, 48, 51, 137]. 
Strikingly, the doxorubicin-resistant FL/Doxo cells 
were more sensitive to the mTORC1 blocker rapamycin 
than the FL5.12, FL/Doxo + MEK1 (CA) and FL/Doxo + 
TP53 (DN) cells (Figure 3C). The FL/Doxo cells displayed 
a very low IC50 to rapamycin. The FL/Doxo + TP53 
(DN) were relatively resistant to the mTORC1 blocker. 
Interactions between suppression of TP53 and sensitivity 
to rapamycin have been previously reported [138,139]. 
One of the side effects of rapamycin treatment is activation 
of ERK [140]. Suppressing mTORC may inhibit aspects 
of cellular senescence [141, 142]. Combining mTOR 
inhibitors with other drugs has shown promise in treatment 
of certain drug-resistant cancers [45, 46, 143]. Resistance 
to rapamycin in certain solid cancers has been associated 
with epithelial to mesenchymal transition (EMT) [144]. 
The FL/Doxo cells were also very sensitive to 
the ABT-737 BCL2 inhibitor, while the FL/Doxo + 
MEK1(CA) were more resistant (Figure 3D). Thus, cells 
which express activated MEK1 were resistant to the BCL2 
inhibitor. Novel BCL2 antagonists are being developed 
to suppress leukemia as well as drug resistance of other 
cancers [24, 145–148] 
The effects of combinations of signal transduction 
inhibitors in suboptimal concentrations to reduce the 
IC50 for doxorubicin were examined (Figure 4). The 
combination of doxorubicin and MG132 reduced 
the doxorubicin IC50 in FL5.12 and FL/Doxo cells 
dramatically. In contrast, the combination of doxorubicin 
and MG-132 reduced the doxorubicin IC50 less in the more 
doxorubicin-resistant FL/Doxo + TP53 (DN) and FL/Doxo 
+ MEK1 (CA) (Figure 4A).
Addition of a suboptimal concentration of the MEK 
inhibitor PD0325891 did not have dramatic effects on the 
doxorubicin IC50 (Figure 4B). In contrast, introduction of 
a suboptimal concentration of rapamycin did reduce the 
IC50 of all cell lines, especially in the FL5.12, FL/Doxo 
and FL/Doxo + MEK1 (CA) cells. These results document 
the importance of the mTORC1 pathway in the response 
to doxorubicin. 
The combination of doxorubicin and suboptimal 
concentrations of the MDM2 inhibitor nutlin-3a yielded 
interesting results as nutlin-3 sensitized cells with wild 
type (WT) TP53 (FL5.12, FL/Doxo and FL/Doxo + 
MEK1 (CA) but not so much in FL/Doxo + TP53 (DN) 
cells (Figure 4D). The FL/Doxo + TP53 (DN) cells still 
have some endogenous WT TP53.
Interestingly, the BCL2 inhibitor ABT-737 
sensitized all the cell Ines to doxorubicin (Figure 5A). 
Likewise, addition of a suboptimal dose of doxorubicin 
sensitized all the cell lines to ABT-737. These results 
indicate the importance of BCL2 and other BCL2-related 
proteins (e.g., BCLXL) that are inhibited by the ABT-737 
inhibitor in the response to rapamycin.
Addition of suboptimal concentrations of the BCL2 
inhibitor did sensitize the doxorubicin resistant FL/Doxo, 
FL/Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) cells 
to the PI3K inhibitor LY294002 more than FL5.12 cells 
(Figure 5A). Likewise, addition of suboptimal concentrations 
of PI3K inhibitor LY294002 did sensitize doxorubicin-
resistant FL/Doxo, FL/Doxo + TP53 (DN) and FL/Doxo 
+ MEK1 (CA) cells to the ABT-737 BCL2 inhibitor more 
than FL5.12 cells (Figure 5B). These results point to the 
importance of BCL2 in the response to PI3K inhibitors. 
The PI3K/PTEN/Akt/mTORC pathway is very important in 
governing the drug-resistance of various cancers [149]. 
Addition of suboptimal concentrations of the MEK 
inhibitor did sensitize the doxorubicin-resistant FL/Doxo, 
FL/Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) 
cells to the BCL2 inhibitor ABT-737 more than FL5.12 
cells (Figure 6A). Addition of suboptimal concentrations 
of BCL2 inhibitor ABT-737 did sensitize-doxorubicin-
resistant FL/Doxo and parental FL5.12 cells to the MEK 
inhibitor PD0325901 more than FL5.12 cells. These 
results point to the importance of BCL2 and related family 
members in the response to MEK inhibitors. 
The proteasomal inhibitor MG132 was able to 
sensitize FL/Doxo, FL5.12 and FL/Doxo + MEK1 (CA) 
cells to the effects of rapamycin (Figure 7A). However, 
addition of a suboptimal dose of the proteasomal inhibitor 
MG132 did not sensitize the FL/Doxo + TP53 (DN) cells 
to the mTORC1 inhibitor rapamycin. 
Addition of a suboptimal doses (500 nM) of the 
MDM2 inhibitor (nutlin-3a) did sensitized the: FL/Doxo, 
FL5.12, FL/Doxo + MEK1 (CA) cells to rapamycin. Less 
effects were observed with FL/Doxo + TP53 (DN) cells 
(Figure 7B).
The expression of various apoptotic regulatory 
genes, MDM2 and activated JNK were examined in the 
cells in the presence and absence of IL-3 and doxorubicin 
and the proteasomal inhibitor MG132 by western 
blot analysis (Figure 8). Previously, we examined the 
expression of TP53 and activated ERK1,2 in these cells 
under the same conditions [21]. Low levels of BIM and 
MDM2 were detected in FL5.12 cells (Figure 8A). In 
contrast, higher levels of BIM and MDM2 were detected 
in FL/Doxo cells. Higher levels of MCL1 transcripts were 
detected in FL5.12 cells upon treatment with 100 and 
1000 nM doxorubicin. Interestingly, the levels of MCL1 
protein were increased upon treatment of FL5.12 cells and 
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10 µM MG132. MCL1 was not detected by western blot 
analysis in FL/Doxo cells. Activated JNK was detected 
in FL5.12 cells upon treatment with 10 µM MG132. The 
pro-apoptotic BAX protein was detected in both FL5.12 
and FL/Doxo cells. These data demonstrate that the drug-
resistant FL/Doxo cells express higher levels of MDM2 
and BIM than the drug-sensitive FL5.12 cells.
The expression of various apoptotic regulators, 
TP53 and activated JNK were examined in FL/
Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) 
cells (Figure 8). High levels of mutant TP53 were of 
observed in FL/Doxo + TP53 (DN) cells, while the 
BAX protein was not detected. In contrast, the TP53 
protein was detected upon treatment of FL/Doxo + 
MEK1 (CA) cells with the proteasomal inhibitor and 
the BAX protein was detected at high levels. The levels 
of BIM and activated JNK were low in both FL/Doxo 
+ MEK1 (CA) cells. 
The levels of some of these and other gene mRNA 
transcripts were also measured by qRT-PCR (Figures 
9–12). Higher levels of MDR1 were detected in the 
doxorubicin-resistant FL/Doxo, FL/Doxo + TP53 (DN) 
and FL/Doxo + MEK1 (CA) cells than the doxorubicin-
sensitive FL5.12 cells. In contrast, higher levels of 
MCL1, BCLXL, BCL2 and YY1 expression were 
detected in the doxorubicin-sensitive FL5.12 than the 
doxorubicin-resistant FL/Doxo, FL/Doxo + TP53 (DN) 
and FL/Doxo + MEK1 (CA) cells. Relatively similar 
levels of Foxo-3a mRNA were detected in these studies. 
In contrast, the presence of TP53 (DN) suppressed the 
levels of BAX detected in the FL/Doxo + TP53 (DN) 
cells than the other cell lines. Higher levels of MRP1 
were detected in FL5.12 and FL/Doxo cells than in FL/
Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) cells. 
The results with MRP1 expression were in contrast with 
the levels of MDR1 expression that indicated more 
MDR1 expression in the drug-resistant FL/Doxo, FL/
Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) cells. 
Thus, it is likely that MDR1 plays a bigger role in 
drug resistance than MRP1 in these cells. Our studies 
document that one of the genes that is increased in the 
doxorubicin-resistant cells is MDR1 which encodes an 
important drug transporter often implicated in drug-
resistance [149–152]. MRP1 is also an important protein 
in drug-resistance [149, 153]. 
The levels of the YY1 protein increased upon 
doxorubicin treatment of FL5.12 cells. Doxorubicin may 
induce TP53 expression which results in increased stability 
of the YY1 protein. Lower levels of YY1 protein were 
induced after doxorubicin treatment of FL/Doxo and FL/
Doxo + TP53 (DN) cells suggesting that in the doxorubicin-
resistant cells less YY1 protein was present after doxorubicin 
treatment than in the doxorubicin-sensitive cells. In contrast, 
the levels of total ERK1,2 protein were similar in all cells in 
the presence and absence of doxorubicin. The stabilization 
of YY1 protein was determined to be independent of the 
MEK and mTORC1 pathways as treatment with MEK and 
mTORC1 inhibitors did not suppress the accumulation of 
YY1 protein, while treatment with the MEK inhibitor, but 
not mTORC1 inhibitor did suppress the detection of activated 
ERK1,2. The NF-kappaB pathway may have effects on the 
levels of YY1 expression [154]. 
The effects of the gene status of TP53 and the 
activity of MEK1 were very important in terms of the 
sensitivity to certain small molecule inhibitors as well 
as on gene expression. TP53 normally regulates the 
expression of numerous miRs that often suppress tumor 
growth. Thus, inhibition of WT TP53 by introduction 
of a DN construct often resulted in therapy-resistance. 
Expression of activated MEK1 also increased drug 
resistance and in some cases altered the response to 
certain small molecule inhibitors. Our results point to 
the complex interactions that can occur by mutations at 
various oncogenes and tumor suppressor proteins that 
can alter sensitivity to chemotherapeutic drugs and small 
molecule signal transduction inhibitors. 
MATERIALS AND METHODS.
Cells and tissue culture conditions
FL5.12, FL/Doxo, FL/Doxo + TP53 (DN) and 
FL/Doxo + MEK1 (CA) were derived and cultured as 
described [21]. IL-3 was purified from the IL-3 dependent 
cell line WEHI-3B as described [21]. MTT proliferation 
assays were performed as described [10–15, 20, 21, 23].
Treatment of cells with signal transduction 
inhibitors and doxorubicin 
FL5.12, FL/Doxo, FL/Doxo + TP53 (DN) and FL/
Doxo + MEK1 (CA) were titrated with the different signal 
transduction inhibitors and doxorubicin as described [10–
15, 20, 21, 23]. Statistical analysis was performed using 
GraphPad Prism.
Western blot analysis
Protein analysis was performed as described with 
the indicated antibodies [21]. 
Quantitative RT-PCR 
Total RNA was isolated from FL5.12 and drug 
resistant derivative cells lines with RNeasy Plus minikits 
(Qiagen, Valencia, CA) and TRIzol reagent (Invitrogen, 
Carlsbad, CA) which was reverse transcribed by 
Superscript III (Invitrogen, Carlsbad, CA). Primers for 
murine genes were obtained from Applied Biosystems, 
Foster City, CA. Real-time RT-PCR was performed with 
TaqMan Gene Expression assays. TaqMan primers are 
listed in Table 1. 
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